{"id":"NCT02121210","sponsor":"Sanofi","briefTitle":"To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)","officialTitle":"An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-04-23","resultsPosted":"2017-06-20","lastUpdate":"2017-06-20"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"sarilumab SAR153191 (REGN88)","otherNames":[]}],"arms":[{"label":"Sarilumab 150 mg q2w","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg q2w","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the immunogenicity of sarilumab administered as monotherapy.\n\nSecondary Objectives:\n\n* To evaluate the other safety aspects of sarilumab administered as monotherapy.\n* To assess the exposure of sarilumab administered as monotherapy.","primaryOutcome":{"measure":"Percentage of Participants With Incidence of Antidrug Antibodies (ADA)","timeFrame":"From Baseline to Week 30 [End of study (EOS)]","effectByArm":[{"arm":"Sarilumab 150 mg q2w","deltaMin":24.6,"sd":null},{"arm":"Sarilumab 200 mg q2w","deltaMin":18.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":28,"countries":["United States","Chile","Czechia","Estonia","Hungary","Poland","Russia"]},"refs":{"pmids":["31090044"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Neutropenia","Upper respiratory tract infection","Injection site erythema","Urinary tract infection","Hypertension"]}}